CN113133957A - 一种植物发酵提拉紧致抗氧化抗疲劳眼贴膜及其制备方法 - Google Patents
一种植物发酵提拉紧致抗氧化抗疲劳眼贴膜及其制备方法 Download PDFInfo
- Publication number
- CN113133957A CN113133957A CN202110445569.9A CN202110445569A CN113133957A CN 113133957 A CN113133957 A CN 113133957A CN 202110445569 A CN202110445569 A CN 202110445569A CN 113133957 A CN113133957 A CN 113133957A
- Authority
- CN
- China
- Prior art keywords
- percent
- component
- plant fermentation
- eye mask
- oxidation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000855 fermentation Methods 0.000 title claims abstract description 38
- 230000004151 fermentation Effects 0.000 title claims abstract description 38
- 230000002929 anti-fatigue Effects 0.000 title claims abstract description 18
- 230000003064 anti-oxidating effect Effects 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title abstract description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 71
- 239000002994 raw material Substances 0.000 claims abstract description 30
- 229930182478 glucoside Natural products 0.000 claims abstract description 29
- -1 glycerol glucoside Chemical class 0.000 claims abstract description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 26
- 239000002131 composite material Substances 0.000 claims abstract description 19
- 238000003756 stirring Methods 0.000 claims abstract description 19
- 238000001914 filtration Methods 0.000 claims abstract description 18
- 150000005846 sugar alcohols Polymers 0.000 claims abstract description 18
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 16
- 239000003974 emollient agent Substances 0.000 claims abstract description 16
- 239000002738 chelating agent Substances 0.000 claims abstract description 15
- 229920001184 polypeptide Polymers 0.000 claims abstract description 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 15
- 239000000043 antiallergic agent Substances 0.000 claims abstract description 13
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims abstract description 12
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims abstract description 12
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 12
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229960001631 carbomer Drugs 0.000 claims abstract description 12
- 239000008367 deionised water Substances 0.000 claims abstract description 12
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 12
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims abstract description 12
- 239000000463 material Substances 0.000 claims abstract description 11
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 claims abstract description 8
- 238000001816 cooling Methods 0.000 claims abstract description 7
- 238000010438 heat treatment Methods 0.000 claims abstract description 7
- 238000007599 discharging Methods 0.000 claims abstract description 4
- 241000196324 Embryophyta Species 0.000 claims description 35
- 235000011187 glycerol Nutrition 0.000 claims description 33
- 239000000284 extract Substances 0.000 claims description 25
- 241000628997 Flos Species 0.000 claims description 22
- 239000000047 product Substances 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 20
- 230000003078 antioxidant effect Effects 0.000 claims description 17
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 17
- 239000003963 antioxidant agent Substances 0.000 claims description 16
- 235000006708 antioxidants Nutrition 0.000 claims description 16
- ODINCKMPIJJUCX-UHFFFAOYSA-N Calcium oxide Chemical compound [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 claims description 13
- 210000000582 semen Anatomy 0.000 claims description 11
- SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical group C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 claims description 10
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 10
- 229940093497 ergothioneine Drugs 0.000 claims description 10
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 10
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 10
- 102000008186 Collagen Human genes 0.000 claims description 9
- 108010035532 Collagen Proteins 0.000 claims description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- 241000121220 Tricholoma matsutake Species 0.000 claims description 9
- 229920001436 collagen Polymers 0.000 claims description 9
- 229920005862 polyol Polymers 0.000 claims description 8
- 150000003077 polyols Chemical class 0.000 claims description 8
- 238000002791 soaking Methods 0.000 claims description 8
- VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 claims description 7
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 claims description 7
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical group [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 7
- 239000001263 FEMA 3042 Substances 0.000 claims description 7
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 claims description 7
- 239000006227 byproduct Substances 0.000 claims description 7
- 239000013078 crystal Substances 0.000 claims description 7
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 7
- 239000011707 mineral Substances 0.000 claims description 7
- 235000010755 mineral Nutrition 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 238000000643 oven drying Methods 0.000 claims description 7
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 7
- 238000010298 pulverizing process Methods 0.000 claims description 7
- 238000007873 sieving Methods 0.000 claims description 7
- 229940119463 sunflower seed extract Drugs 0.000 claims description 7
- 235000015523 tannic acid Nutrition 0.000 claims description 7
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 claims description 7
- 229920002258 tannic acid Polymers 0.000 claims description 7
- 229940033123 tannic acid Drugs 0.000 claims description 7
- 239000000292 calcium oxide Substances 0.000 claims description 6
- 235000012255 calcium oxide Nutrition 0.000 claims description 6
- 240000000588 Hericium erinaceus Species 0.000 claims description 5
- 235000007328 Hericium erinaceus Nutrition 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 3
- 230000003472 neutralizing effect Effects 0.000 claims description 3
- 230000003647 oxidation Effects 0.000 claims description 3
- 238000007254 oxidation reaction Methods 0.000 claims description 3
- KIUVQMGRTDPAFR-UHFFFAOYSA-N benzoic acid 2-hydroxy-2-phenylpropanamide Chemical group C(C1=CC=CC=C1)(=O)O.OC(C(=O)N)(C)C1=CC=CC=C1 KIUVQMGRTDPAFR-UHFFFAOYSA-N 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims 1
- 206010070834 Sensitisation Diseases 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 16
- 208000003464 asthenopia Diseases 0.000 abstract description 5
- 210000003491 skin Anatomy 0.000 description 21
- 210000004185 liver Anatomy 0.000 description 19
- 239000004744 fabric Substances 0.000 description 14
- 230000004438 eyesight Effects 0.000 description 11
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 241000723353 Chrysanthemum Species 0.000 description 8
- 235000007516 Chrysanthemum Nutrition 0.000 description 8
- 244000037364 Cinnamomum aromaticum Species 0.000 description 7
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 7
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 6
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 6
- 206010013774 Dry eye Diseases 0.000 description 6
- 240000000249 Morus alba Species 0.000 description 6
- 235000008708 Morus alba Nutrition 0.000 description 6
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 244000020518 Carthamus tinctorius Species 0.000 description 5
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 5
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 5
- 102000013691 Interleukin-17 Human genes 0.000 description 5
- 108050003558 Interleukin-17 Proteins 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000003796 beauty Effects 0.000 description 5
- VKIJBOMCWLTQBD-UHFFFAOYSA-N benzoic acid N-(2-hydroxyphenyl)propanamide Chemical group C(C1=CC=CC=C1)(=O)O.C(CC)(=O)NC1=C(C=CC=C1)O VKIJBOMCWLTQBD-UHFFFAOYSA-N 0.000 description 5
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 5
- 210000004561 lacrimal apparatus Anatomy 0.000 description 5
- 239000002398 materia medica Substances 0.000 description 5
- 230000036407 pain Effects 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 241001113925 Buddleja Species 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 4
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 4
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 4
- 241000475481 Nebula Species 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 206010034960 Photophobia Diseases 0.000 description 4
- 244000269722 Thea sinensis Species 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 239000013068 control sample Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 3
- 206010010726 Conjunctival oedema Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 108010003541 Platelet Activating Factor Proteins 0.000 description 3
- 241001085205 Prenanthella exigua Species 0.000 description 3
- 206010047513 Vision blurred Diseases 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- 241000233866 Fungi Species 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010023644 Lacrimation increased Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 230000004377 improving vision Effects 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 230000004317 lacrimation Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 229940119485 safflower extract Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- 208000005494 xerophthalmia Diseases 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 206010053631 Bone swelling Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 244000035851 Chrysanthemum leucanthemum Species 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 244000060234 Gmelina philippensis Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 235000003805 Musa ABB Group Nutrition 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 208000001140 Night Blindness Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 235000015266 Plantago major Nutrition 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 244000305267 Quercus macrolepis Species 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 206010040830 Skin discomfort Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 206010048259 Zinc deficiency Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 229930182489 iridoid glycoside Natural products 0.000 description 1
- 150000008145 iridoid glycosides Chemical class 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- KINGXFAMZNIVNL-SXQDSXCISA-N safflor yellow A Natural products OC[C@@H]1O[C@H]2[C@H](OC3=C2C(=O)C(=C(O)C=Cc4ccc(O)cc4)C(=O)[C@]3(O)[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)[C@@H](O)[C@H]1O KINGXFAMZNIVNL-SXQDSXCISA-N 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000001052 yellow pigment Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0208—Tissues; Wipes; Patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/604—Alkylpolyglycosides; Derivatives thereof, e.g. esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/30—Characterized by the absence of a particular group of ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
一种植物发酵提拉紧致抗氧化抗疲劳眼贴膜及其制备方法,该眼贴膜包括A组份、B组份、C组份,其中:A组份包括多元醇、卡波姆、羟乙基纤维素、螯合剂、对羟基苯乙酮、已二醇、去离子水;B组份包括:三乙醇胺;C组份包括润肤剂、复合植物发酵原料、小分子多肽紧肤剂、抗敏剂、抗氧化原料、甘油葡糖苷;其制备方法包括如下步骤:(1)将羟乙基纤维素分散搅匀溶解后,加入用多元醇分散后的卡波姆,加热溶解再加入A组份中剩余组份搅拌均匀、保温;(2)加入三乙醇胺搅拌分散均匀;(3)加入预先用去离子水分散溶解后的C组份物料,搅拌均匀;(4)降温过滤出料得到成品。本发明产品可缓解眼部疲劳,提拉紧致眼部肌肤效果良好。
Description
技术领域
本发明涉及美容护肤品技术领域,尤其涉及一种植物发酵提拉紧致抗氧化抗疲劳眼贴膜及其制备方法。
背景技术
随着人民生活水平的提高,化妆品尤其是美容护肤品越来越进入人们的日常生活中,其中眼膜类产品越来越成为人们追求眼部肌肤不老神话的美好生活的辅助用品。随着环境的变化以及生活节奏的加快,年龄已不再是评判“衰老”的界限,人们通常把那些20岁出头就显现出面部松弛、皱纹、眼疲劳等症状统称为“衰老”。对于随着年龄的增长,人体皮肤中的成纤维细胞和胶原蛋白的流失越来越快,造成肌肤松弛,眼脸部肌肤松弛,细纹隐现。年轻人因为有太多不良生活和饮食习惯,例如睡眠不充足、不规律、经常熬夜、工作压力大、酗酒吸烟等,都会导致眼部的自由基激增而无法被肌肤代谢。而使用护肤品不当,或是去角质过于频繁、卸妆不彻底,也都是加重胶原蛋白流失的元凶。
为了抵抗初老症,制造一种能够紧致肌肤,深层保湿,修复受损的肌肤的美容化妆品成了人们的愿望。同时,缓解疲劳,焕肤新生也是爱美人士的首选。为了弥补和修复这些肌肤损伤,产品中应用的科学技术和原料成分非常重要。使用快速透皮吸收技术的紧致修复美白面霜和美白面膜成了解决这一系列问题的必要手段。
同时,鉴于无添加防腐剂成分的化妆品越来越受到市场的喜欢,有必要在中高端护理产品采用无添加防腐剂技术,避免添加防腐剂带来的皮肤不适反应。
发明内容
针对现有技术的不足,本发明所解决的技术问题采用无添加防腐剂技术制造缓解眼部疲劳及提拉紧致眼部肌肤效果良好的美容护肤品。
为解决上述技术问题,本发明采用的技术方案是一种植物发酵提拉紧致抗氧化抗疲劳眼贴膜,包括A组份、B组份、C组份,其中:
所述A组份主要由以下质量百分比成:
多元醇3-10%,
卡波姆0.05-0.2%,
羟乙基纤维素0.05-0.2%,
螯合剂0.05-0.1%,
对羟基苯乙酮0.3-0.8%,
已二醇0.5-0.8%,
去离子水75.95-90.869%;
所述B组份主要由以下质量百分比组成:
三乙醇胺0.05-0.20%;
所述C组份主要由以下质量百分比组成:
润肤剂0.01-0.55%,
复合植物发酵原料:0.5-10.0%,
小分子多肽紧肤剂1.0-5.0%,
抗敏剂0.1-1.0%,
抗氧化原料:0.1-2%,
甘油葡糖苷:0.1-0.5%;
上述各组份的质量百分比之和为100%。
优选地,所述多元醇为丁二醇、丙二醇、甘油中的至少一种。
优选地,所述螯合剂为乙二胺四乙酸二钠。
优选地,所述复合植物发酵原料为密蒙花、红花、菊花、桑叶、决明子中的至少一种提取物。
优选地,所述小分子多肽紧肤剂由如下质量组分混合而成:胶原蛋白为0.1-5.0%、乙酰基6肽-8为0.1-4.0%、棕榈酰5肽-4为0.1-4.0%。
优选地,所述润肤剂为透明质酸钠、向日葵籽提取物中的至少一种。进一步,为透明质酸钠0.01-0.05%与向日葵籽提取物0.1-0.5%的混合物。
优选地,所述抗敏剂为羟苯基丙酰胺苯甲酸。
优选地,所述抗氧化原料为松茸、猴头菇中的至少一种的提取物,进一步,所述提取物为麦角硫因。
优选地,所述甘油葡糖苷为卷柏的提取物,其提取方式采用多元醇提取,将卷柏烘干后粉碎过100目筛后加入10-12倍的丁二醇在50-60℃浸泡48-72小时,过滤残渣后加入生石灰水去除矿物质和鞣酸类副产物,过滤后浓缩得到甘油葡糖苷结晶物后溶于丁二醇,制成5%的甘油葡糖苷。
本发明要解决的另一个技术问题是提供上述眉毛增长滋养液的制备方法。
为此,本发明提供的技术方案是一种植物发酵提拉紧致抗氧化抗疲劳眼贴膜的制备方法,包括以下步骤:
(1)将A组份中的羟乙基纤维素加入搅拌的水中,分散搅匀后升温到50-55℃溶解完全后,加入用多元醇分散后的卡波姆,然后加热至75-85℃溶解完全,再加入A组份中剩余组份搅拌均匀,保温10分钟;
(2)调低搅拌速度后,加入B组份中的三乙醇胺,中和搅拌分散均匀;
(3)缓慢降温到55℃以下,加入预先用去离子水分散溶解后的C组份物料,搅拌均匀;
(4)降温到40℃以下,过滤出料得到成品。
与现有技术相比,本发明产品富含复合植物发酵原料、透明质酸钠、松茸提取液、向日葵籽提取物等活性成分,使用后可缓解眼部疲劳,提拉紧致眼部肌肤效果良好。
具体实施方式
下面结合实施例和实验例对本发明的具体实施方式做进一步的说明,但不是对本发明的限定。
实施例1
一种植物发酵提拉紧致抗氧化抗疲劳眼贴膜,包括A组份、B组份、C组份,其中:
A组份主要由以下质量百分比成:
多元醇3%,
卡波姆0.2%,
羟乙基纤维素0.05%,
螯合剂0.1%,
对羟基苯乙酮0.3%,
已二醇0.8%,
去离子水82.74%;
B组份主要由以下质量百分比组成:
三乙醇胺0.20%;
C组份主要由以下质量百分比组成:
润肤剂0.01%,
复合植物发酵原料:10.0%,
小分子多肽紧肤剂1.0%,
抗敏剂1.0%,
抗氧化原料:0.1%,
甘油葡糖苷:0.5%;
上述各组份的质量百分比之和为100%。
多元醇为丁二醇。
螯合剂为乙二胺四乙酸二钠。
复合植物发酵原料为密蒙花、红花、菊花、桑叶、决明子中的提取物。
小分子多肽紧肤剂由如下质量组分混合而成:胶原蛋白为0.1-5.0%、乙酰基6肽-8为0.1-4.0%、棕榈酰5肽-4为0.1-4.0%。
润肤剂为透明质酸钠。
抗敏剂为羟苯基丙酰胺苯甲酸。
抗氧化原料为麦角硫因。
甘油葡糖苷为卷柏的提取物,其提取方式采用多元醇提取,将卷柏烘干后粉碎过100目筛后加入10-12倍的丁二醇在50-60℃浸泡48-72小时,过滤残渣后加入生石灰水去除矿物质和鞣酸类副产物,过滤后浓缩得到甘油葡糖苷结晶物后溶于丁二醇,制成5%的甘油葡糖苷。
实施例2
一种植物发酵提拉紧致抗氧化抗疲劳眼贴膜,包括A组份、B组份、C组份,其中:
A组份主要由以下质量百分比成:
多元醇9.79%,
卡波姆0.2%,
羟乙基纤维素0.05%,
螯合剂0.1%,
对羟基苯乙酮0.3%,
已二醇0.8%,
去离子水75.95%;
B组份主要由以下质量百分比组成:
三乙醇胺0.20%;
C组份主要由以下质量百分比组成:
润肤剂0.01%,
复合植物发酵原料:10.0%,
小分子多肽紧肤剂1.0%,
抗敏剂1.0%,
抗氧化原料:0.1%,
甘油葡糖苷:0.5%;
上述各组份的质量百分比之和为100%。
多元醇为丙二醇。
螯合剂为乙二胺四乙酸二钠。
复合植物发酵原料为密蒙花、红花、菊花、桑叶、决明子中的提取物。
小分子多肽紧肤剂由如下质量组分混合而成:胶原蛋白为0.1-5.0%、乙酰基6肽-8为0.1-4.0%、棕榈酰5肽-4为0.1-4.0%。
润肤剂为向日葵籽提取物。
抗敏剂为羟苯基丙酰胺苯甲酸。
抗氧化原料为麦角硫因。
甘油葡糖苷为卷柏的提取物,其提取方式采用多元醇提取,将卷柏烘干后粉碎过100目筛后加入10-12倍的丁二醇在50-60℃浸泡48-72小时,过滤残渣后加入生石灰水去除矿物质和鞣酸类副产物,过滤后浓缩得到甘油葡糖苷结晶物后溶于丁二醇,制成5%的甘油葡糖苷。
实施例3
一种植物发酵提拉紧致抗氧化抗疲劳眼贴膜,包括A组份、B组份、C组份,其中:
A组份主要由以下质量百分比成:
多元醇5%,
卡波姆0.1%,
羟乙基纤维素0.1%,
螯合剂0.08%,
对羟基苯乙酮0.5%,
已二醇0.7%,
去离子水83.32%;
B组份主要由以下质量百分比组成:
三乙醇胺0.1%;
C组份主要由以下质量百分比组成:
润肤剂0.3%,
复合植物发酵原料:5%,
小分子多肽紧肤剂3%,
抗敏剂0.5%,
抗氧化原料:1%,
甘油葡糖苷:0.3%;
上述各组份的质量百分比之和为100%。
多元醇为甘油。
螯合剂为乙二胺四乙酸二钠。
复合植物发酵原料为密蒙花、红花、菊花、桑叶、决明子中的提取物。
小分子多肽紧肤剂由如下质量组分混合而成:胶原蛋白为0.1-5.0%、乙酰基6肽-8为0.1-4.0%、棕榈酰5肽-4为0.1-4.0%。
润肤剂为透明质酸钠0.01-0.05%与向日葵籽提取物0.1-0.5%的混合物。
抗敏剂为羟苯基丙酰胺苯甲酸。
抗氧化原料为麦角硫因。
甘油葡糖苷为卷柏的提取物,其提取方式采用多元醇提取,将卷柏烘干后粉碎过100目筛后加入10-12倍的丁二醇在50-60℃浸泡48-72小时,过滤残渣后加入生石灰水去除矿物质和鞣酸类副产物,过滤后浓缩得到甘油葡糖苷结晶物后溶于丁二醇,制成5%的甘油葡糖苷。
实施例4
一种植物发酵提拉紧致抗氧化抗疲劳眼贴膜,包括A组份、B组份、C组份,其中:
A组份主要由以下质量百分比成:
多元醇3%,
卡波姆0.05%,
羟乙基纤维素0.2%,
螯合剂0.05%,
对羟基苯乙酮0.8%,
已二醇0.5%,
去离子水90.869%;
B组份主要由以下质量百分比组成:
三乙醇胺0.05%;
C组份主要由以下质量百分比组成:
润肤剂0.55%,
复合植物发酵原料:0.5%,
小分子多肽紧肤剂1.231%,
抗敏剂0.1%,
抗氧化原料:2%,
甘油葡糖苷:0.1%;
上述各组份的质量百分比之和为100%。
多元醇为丁二醇。
螯合剂为乙二胺四乙酸二钠。
复合植物发酵原料为密蒙花、红花、菊花、桑叶、决明子中的提取物。
小分子多肽紧肤剂由如下质量组分混合而成:胶原蛋白为0.1-5.0%、乙酰基6肽-8为0.1-4.0%、棕榈酰5肽-4为0.1-4.0%。
润肤剂为透明质酸钠0.01-0.05%与向日葵籽提取物0.1-0.5%的混合物。
抗敏剂为羟苯基丙酰胺苯甲酸。
抗氧化原料为麦角硫因。
甘油葡糖苷为卷柏的提取物,其提取方式采用多元醇提取,将卷柏烘干后粉碎过100目筛后加入10-12倍的丁二醇在50-60℃浸泡48-72小时,过滤残渣后加入生石灰水去除矿物质和鞣酸类副产物,过滤后浓缩得到甘油葡糖苷结晶物后溶于丁二醇,制成5%的甘油葡糖苷。
实施例5
一种植物发酵提拉紧致抗氧化抗疲劳眼贴膜,包括A组份、B组份、C组份,其中:
A组份主要由以下质量百分比成:
多元醇10%,
卡波姆0.05%,
羟乙基纤维素0.2%,
螯合剂0.05%,
对羟基苯乙酮0.8%,
已二醇0.5%,
去离子水80.1%;
B组份主要由以下质量百分比组成:
三乙醇胺0.05%;
C组份主要由以下质量百分比组成:
润肤剂0.55%,
复合植物发酵原料:0.5%,
小分子多肽紧肤剂5.0%,
抗敏剂0.1%,
抗氧化原料:2%,
甘油葡糖苷:0.1%;
上述各组份的质量百分比之和为100%。
多元醇为甘油。
螯合剂为乙二胺四乙酸二钠。
复合植物发酵原料为密蒙花、红花、菊花、桑叶、决明子中的提取物。
小分子多肽紧肤剂由如下质量组分混合而成:胶原蛋白为0.1-5.0%、乙酰基6肽-8为0.1-4.0%、棕榈酰5肽-4为0.1-4.0%。
润肤剂为透明质酸钠0.01-0.05%与向日葵籽提取物0.1-0.5%的混合物。
抗敏剂为羟苯基丙酰胺苯甲酸。
抗氧化原料为麦角硫因。
甘油葡糖苷为卷柏的提取物,其提取方式采用多元醇提取,将卷柏烘干后粉碎过100目筛后加入10-12倍的丁二醇在50-60℃浸泡48-72小时,过滤残渣后加入生石灰水去除矿物质和鞣酸类副产物,过滤后浓缩得到甘油葡糖苷结晶物后溶于丁二醇,制成5%的甘油葡糖苷。
上述实施例1至5制备方法,包括以下步骤:
(1)将A组份中的羟乙基纤维素加入搅拌的水中,分散搅匀后升温到50-55℃溶解完全后,加入用多元醇分散后的卡波姆,然后加热至75-85℃溶解完全,再加入A组份中剩余组份搅拌均匀,保温10分钟;
(2)调低搅拌速度后,加入B组份中的三乙醇胺,中和搅拌分散均匀;
(3)缓慢降温到55℃以下,加入预先用去离子水分散溶解后的C组份物料,搅拌均匀;
(4)降温到40℃以下,过滤出料得到成品。
本发明产品中的复合植物发酵原料为密蒙花、红花、菊花、桑叶、决明子中的提取物。其中:
密蒙花的提取物,其性微寒、味甘,归肝经,有清热养肝、明目退翳功效,用于目赤肿痛、多泪羞明、眼生翳膜、肝虚目暗、视物昏花,为眼科常用药物。密蒙花含有黄酮类、挥发油、黄色素、三萜类、环烯醚萜苷类等多种化学成分,具有抗炎、免疫调节、降血糖、抗氧化、抗血管内皮细胞增生等作用,临床用于干眼症、白内障、角膜软化、两眼羞明等疗效较好。食疗也用于眼部疾患。
红花的提取物,性味辛温,入心肝经,具有活血祛瘀,散湿去肿等功效。的红花提取物《本草汇言》云:红花,破血,行血,和血,调血之药也。红花中的红花黄色素、红花多糖、可以拮抗血小板活化因子,抑制血小板活化因子(PAF)诱发的血小板聚集和减轻炎症反应。此外,红花还有抗凝血及血栓、免疫调节作用和抗肿瘤作用。
菊花的提取物,性辛、甘、苦,微寒。归肺、肝经。其功效为疏散风热、平抑肝阳、清肝明目和清热解毒。常服菊花茶,不仅能让人头脑清醒、双目明亮,特别是还能对肝火旺、用眼过度等原因而导致的双眼干涩有较好的疗效。菊花提取物《神农本草经》称:菊花味苦、平、主风、头晕、肿痛、目欲泪出;李时珍《本草纲目》称:利五脉、调四肢,治头风热、脑骨肿痛、养目血、去翳膜、主肝气不足;《埤雅》称,野菊花“可入药,久服令人长生、明日、治头晕、安肠胃、去目翳”;《本草备要》认为,野菊花性甘苦微寒,有疏风热,清头目之功。
桑叶的提取物,味苦、甘,性微寒。归肺、肝经。清凉散降,该品轻清疏散,外能疏散风热,内能清肺、平肝、明目,常用治风热感冒、燥热伤肺、肝阳上亢及风热或肝火目赤感冒、燥热伤肺、肝阳上亢及风热或肝火目赤肿痛、肝阴不足之眼目昏花。此外,又能凉血止血。
《本草新编》:桑叶之功,更佳于桑皮,最善补骨中之髓、添肾中之精,止身中之汗,填脑明目,活血生津。桑叶中富含芸香苷,槲皮素等黄酮类成分,另外还有生物碱,植物甾醇桑叶多糖等各种成分。桑叶不仅可用于风热引起的目赤羞明,且可清肝火,对肝火上炎的目赤肿痛,可与菊花、决明子、车前子等配合应用。至于肝阴不足,眼目昏花。
决明子的提取物,味苦、甘、咸,性微寒,入肝、肾、大肠经;清肝明目,润肠通便,治疗便秘及高血脂,高血压。清肝明目,利水通便,有缓泻作用,降血压降血脂。用于目赤涩痛,羞明多泪,头痛眩晕,目暗不明,大便秘结。《神农本草经》:治青盲,目淫肤赤白膜,眼赤痛,泪出,久服益精光。《中华本草》曰:“清肝益肾,明目,利水通便。主治目赤肿痛,羞明泪多、青盲、雀目、头痛头晕、视物昏暗、肝硬化腹水、小便不利,习惯性便秘。外治肿毒、癣疾”。决明子又称“还瞳子”,富含有多种维生素和氨基酸、脂肪、碳水化合物等,其保健功能日益受到人们的重视。决明子具有清肝火、祛风湿、益肾明目等功能,常饮决明子茶,可使血压正常,大便通畅,老眼不花。临床试验证明,喝决明子茶可以清肝明目、防止视力模糊、降血压、降血脂、减少胆固醇等,对于防治冠心病、高血压都有不错的疗效;而且决明子富含维生素A及锌,可防治夜盲症以及避免小儿缺锌。
复合植物发酵原料对眼睛干涩的作用,通过去势方法建立雄兔干眼泪腺模型,观察不同浓度对雄兔干眼泪腺组织中炎性细胞因子:细胞间黏附分子-1(IntercellularCell Adhesion Molecule-1,ICAM-1),白细胞介素-6(Interleukin-6,IL-6)与白细胞介素-17(Interleukin-17,IL-17)在泪腺细胞中的表达的影响从而探讨其疗效。采用雄兔去势的方法建立有效的干眼症动物模型。干眼模型雄兔泪腺组织结构欠清晰,ICAM-1、IL-6与IL-17在细胞膜与细胞浆中的表达明显增多具有类似雄激素的作用,能降低ICAM-1、IL-6与IL-17的在泪腺组织中的表达,进而减轻泪腺的炎症反应,既保证了泪液分泌量,又维持了泪膜的稳定性,起到了治疗干眼的效果。密蒙花含有大量的黄酮类成分,有些结构片段和雄激素类似,但更温和同时还有抗氧化抗炎的活性,同时不易形成抗药性。
本发明产品中的抗氧化原料为松茸、猴头菇中的至少一种的提取物,该提取物为麦角硫因,其中:
松茸是一种非常罕见的口蘑,分布在未受污染的高山原始森林中,它们生长于松树或栎树的根部,生长非常缓慢,人工栽培还没有成功。松茸营养丰富,可以帮助清除自由基,延缓组织器官衰退,促进新陈代谢,被誉为“真菌之王”。
猴头菇是富含蛋白质、氨基酸、维生素和无机盐的中药,用于治疗胃炎、胃溃疡,提高免疫力,抗衰老等,民间有言:“多吃猴菇,返老还童”。
松茸、猴头菇中提取物中含有高浓度的麦角硫因,麦角硫因的作用有保护皮肤细胞的DNA 2,减少细胞凋亡,保护线粒体免受UVA损伤,保护抗凋亡蛋白Bcl-2,减少表皮细胞凋亡,保护细胞免受紫外损伤,清除自由基,体内试验:减少色斑和细纹,改善皮肤粗糙度,提高皮肤弹性。
为了更好的说明本发明的有益效果,进行对比半眼的紧致,舒缓和抗氧化效果评价实验:
实验例1:
6位受测试者采用半眼试验,把本发明产品浸于膜基布后敷在受试者半眼部位涂抹均匀,另一半眼部位使用的是浸于5%甘油和水做的对照样精华液的膜基布,5-15分钟后取下膜基布,轻轻按摩吸收后对比另一半眼部位。
实验结果表明:
(1)本发明产品经过膜布敷上时间5-15分钟吸收,高效深入肌肤底层,记忆恢复肌肤年轻位置,与另一半眼部位使用5%甘油和水做的对照样精华液进行比较,受测试4人均明显感觉所使用眼膜的那一半眼肌肤细纹消失,有紧致感,眼部舒缓效果明显。受测试2人感觉有一定收紧感觉,但反映精华液偏稀有往下滴现象;
(2)取下面膜布后轻轻按摩吸收后,受测试6人明显感觉使用部位亮白、柔嫩,细纹淡化,舒缓疲劳,干后,使用的半眼部位肌肉紧实而有弹性。
实验例2:
6位受测试者采用半眼试验,把本发明产品浸于膜基布后敷在受试者半眼涂抹均匀,另一半眼部位使用的膜基布是浸于5%甘油和水做的对照样精华液,5-15分钟后取下膜基布,轻轻按摩吸收后对比另一半眼部位。
实验结果表明:
本发明产品经过面膜布敷上时间5-15分钟后取下,经按摩吸收,受测试6人均明显感觉所使用半眼肌肤收紧感,眼部舒缓效果明显。同时,受测试6人明显感觉使用部位亮白、柔嫩,细纹淡化。干后,使用的半眼部位细纹少,有弹性。
实验例3:
6位受测试者采用半眼试验,把本发明产品浸于眼膜基布后敷在受试者半眼部位涂抹均匀,另一半眼部位使用的膜基布是浸于5%甘油和水做的对照样精华液,5-8分钟后取下面膜基布,轻轻按摩吸收后对比另一半眼部位。
实验结果表明:
测试实施样板经过面膜布敷上时间5-15分钟后取下按摩吸收,测试6人均明显感觉所使用半眼肌肤收紧感,眼部舒缓效果明显。同时,6人明显感觉使用部位亮白、柔嫩,细纹淡化。干后使用的半眼细纹少,有弹性。
综上所述,本发明产品富含复合植物发酵原料、透明质酸钠、松茸提取液、向日葵籽提取物等活性成分,使用后可缓解眼部疲劳,提拉紧致眼部肌肤效果良好。
以上结合实施例和实验例对本发明的实施方式作出了详细说明,但本发明不局限于所描述的实施方式。对于本领域技术人员而言,在不脱离本发明的原理和精神的情况下,对这些实施方式进行各种变化、修改、替换和变型仍落入本发明的保护范围内。
Claims (10)
1.一种植物发酵提拉紧致抗氧化抗疲劳眼贴膜,其特征在于,包括A组份、B组份、C组份,其中:
所述A组份主要由以下质量百分比成:
多元醇3-10%,
卡波姆0.05-0.2%,
羟乙基纤维素0.05-0.2%,
螯合剂0.05-0.1%,
对羟基苯乙酮0.3-0.8%,
已二醇0.5-0.8%,
去离子水75.95-90.869%;
所述B组份主要由以下质量百分比组成:
三乙醇胺0.05-0.20%;
所述C组份主要由以下质量百分比组成:
润肤剂0.01-0.55%,
复合植物发酵原料:0.5-10.0%,
小分子多肽紧肤剂1.0-5.0%,
抗敏剂0.1-1.0%,
抗氧化原料:0.1-2%,
甘油葡糖苷:0.1-0.5%;
上述各组份的质量百分比之和为100%。
2.根据权利要求1所述的植物发酵提拉紧致抗氧化抗疲劳眼贴膜,其特征在于,所述多元醇为丁二醇、丙二醇、甘油中的至少一种,所述螯合剂为乙二胺四乙酸二钠,所述复合植物发酵原料为密蒙花、红花、菊花、桑叶、决明子中的至少一种提取物。
3.根据权利要求1所述的植物发酵提拉紧致抗氧化抗疲劳眼贴膜,其特征在于,所述小分子多肽紧肤剂由如下质量组分混合而成:胶原蛋白为0.1-5.0%、乙酰基6肽-8为0.1-4.0%、棕榈酰5肽-4为0.1-4.0%。
4.根据权利要求1所述的植物发酵提拉紧致抗氧化抗疲劳眼贴膜,其特征在于,所述润肤剂为透明质酸钠、向日葵籽提取物中的至少一种。
5.根据权利要求4所述的植物发酵提拉紧致抗氧化抗疲劳眼贴膜,其特征在于,所述润肤剂为透明质酸钠0.01-0.05%与向日葵籽提取物0.1-0.5%的混合物。
6.根据权利要求1所述的植物发酵提拉紧致抗氧化抗疲劳眼贴膜,其特征在于,所述抗敏剂为羟苯基丙酰胺苯甲酸。
7.根据权利要求1所述的植物发酵提拉紧致抗氧化抗疲劳眼贴膜,其特征在于,所述抗氧化原料为松茸、猴头菇中的至少一种的提取物。
8.根据权利要求7所述的植物发酵提拉紧致抗氧化抗疲劳眼贴膜,其特征在于,所述提取物为麦角硫因。
9.根据权利要求1所述的植物发酵提拉紧致抗氧化抗疲劳眼贴膜,其特征在于,所述甘油葡糖苷为卷柏的提取物,其提取方式采用多元醇提取,将卷柏烘干后粉碎过100目筛后加入10-12倍的丁二醇在50-60℃浸泡48-72小时,过滤残渣后加入生石灰水去除矿物质和鞣酸类副产物,过滤后浓缩得到甘油葡糖苷结晶物后溶于丁二醇,制成5%的甘油葡糖苷。
10.一种如权利要求1至9任一项所述的植物发酵提拉紧致抗氧化抗疲劳眼贴膜的制备方法,其特征在于,包括以下步骤:
(1)将A组份中的羟乙基纤维素加入搅拌的水中,分散搅匀后升温到50-55℃溶解完全后,加入用多元醇分散后的卡波姆,然后加热至75-85℃溶解完全,再加入A组份中剩余组份搅拌均匀,保温10分钟;
(2)调低搅拌速度后,加入B组份中的三乙醇胺,中和搅拌分散均匀;
(3)缓慢降温到55℃以下,加入预先用去离子水分散溶解后的C组份物料,搅拌均匀;
(4)降温到40℃以下,过滤出料得到成品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110445569.9A CN113133957A (zh) | 2021-04-25 | 2021-04-25 | 一种植物发酵提拉紧致抗氧化抗疲劳眼贴膜及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110445569.9A CN113133957A (zh) | 2021-04-25 | 2021-04-25 | 一种植物发酵提拉紧致抗氧化抗疲劳眼贴膜及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113133957A true CN113133957A (zh) | 2021-07-20 |
Family
ID=76811823
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110445569.9A Pending CN113133957A (zh) | 2021-04-25 | 2021-04-25 | 一种植物发酵提拉紧致抗氧化抗疲劳眼贴膜及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113133957A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113876677A (zh) * | 2021-10-29 | 2022-01-04 | 孙景强 | 一种石斛清润眼膜及其制备方法 |
CN114177279A (zh) * | 2021-12-23 | 2022-03-15 | 广西信业生物技术有限公司 | 一种纳米微囊结构的医用眼贴及制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107648153A (zh) * | 2017-09-29 | 2018-02-02 | 天津北洋百川生物技术有限公司 | 一种含菊花发酵液的精华液及其制备方法和应用 |
CN109481373A (zh) * | 2017-09-11 | 2019-03-19 | 广州尊伊化妆品有限公司 | 提拉紧致抗初老功效的美白v脸面膜贴及其制备方法 |
CN110934925A (zh) * | 2019-12-31 | 2020-03-31 | 傅碧池 | 一种缓解视疲劳眼贴的中药组合物 |
-
2021
- 2021-04-25 CN CN202110445569.9A patent/CN113133957A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109481373A (zh) * | 2017-09-11 | 2019-03-19 | 广州尊伊化妆品有限公司 | 提拉紧致抗初老功效的美白v脸面膜贴及其制备方法 |
CN107648153A (zh) * | 2017-09-29 | 2018-02-02 | 天津北洋百川生物技术有限公司 | 一种含菊花发酵液的精华液及其制备方法和应用 |
CN110934925A (zh) * | 2019-12-31 | 2020-03-31 | 傅碧池 | 一种缓解视疲劳眼贴的中药组合物 |
Non-Patent Citations (3)
Title |
---|
乔尼.鲍登: "《地球上最健康的150种食材》", 中国轻工业出版社 * |
张建中: "《皮肤科医生护肤课》", 31 August 2020, 科学技术文献出版社 * |
王立晖: "《生物活性多肽特性与营养学应用研究》", 30 November 2016, 天津大学出版社 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113876677A (zh) * | 2021-10-29 | 2022-01-04 | 孙景强 | 一种石斛清润眼膜及其制备方法 |
CN114177279A (zh) * | 2021-12-23 | 2022-03-15 | 广西信业生物技术有限公司 | 一种纳米微囊结构的医用眼贴及制备方法 |
CN114177279B (zh) * | 2021-12-23 | 2024-03-26 | 广西信业生物技术有限公司 | 一种纳米微囊结构的医用眼贴及制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103932970A (zh) | 一种中草药祛斑组合化妆品及其制备方法 | |
CN105213284A (zh) | 一种祛痘保湿霜及其制备方法 | |
CN108653013A (zh) | 一种植物保湿水润晒后修复霜及其制备方法 | |
JP5646117B2 (ja) | 発毛促進剤及び製造方法 | |
CN113133957A (zh) | 一种植物发酵提拉紧致抗氧化抗疲劳眼贴膜及其制备方法 | |
CN111617197A (zh) | 一种生发养发的中药组合物及其制备方法与应用 | |
CN105288597B (zh) | 一种治疗皮肤色素沉着的药物 | |
CN112107612B (zh) | 补气养血、美容养颜的中药组合物及其制备方法和应用 | |
CN105125467A (zh) | 一种祛红血丝乳液及其制备方法 | |
CN104922051A (zh) | 一种缓解眼角皱纹眼袋的中药眼霜及其制备方法 | |
CN108542829A (zh) | 一种植物保湿防晒霜及其制备方法 | |
CN105213256A (zh) | 一种舒敏祛红柔肤水及其制备方法 | |
CN104473153B (zh) | 一种美容养颜的桑葚口服液及其制备方法 | |
KR101999675B1 (ko) | 관상동맥성 심장질환의 예방과 치료용 생약조성물 | |
CN102266427B (zh) | 一种用于美容养颜的鹿茸当归酒及其制备方法和应用 | |
CN110680794A (zh) | 一种纯天然无化学添加剂的食品级珍珠蜂蜜茶味口腔护理组合物的绿色制备方法及其应用 | |
CN109646359B (zh) | 一种具有清洁净化和美容养颜功效的玫瑰木耳泥膜膏及其制备方法 | |
CN113318048A (zh) | 一种具有增加皮肤保湿效果的女性私密膜配方 | |
CN111346173A (zh) | 中药组合物、中药精油、中药护肤品和制备方法 | |
CN105342923A (zh) | 一种预防嘴唇干裂的唇膏及其制备方法 | |
CN112353883A (zh) | 治疗近视飞蚊症的眼药水的制备方法 | |
CN105168091A (zh) | 一种祛红血丝面膜粉及其制备方法 | |
CN109394869A (zh) | 蒲蓉爽乳霜及其制备方法 | |
CN111110817A (zh) | 一种治疗眼疾的中药组合物、制备方法及其应用 | |
CN108403603A (zh) | 一种樱桃山柰美容祛斑天然中药面膜膏及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210720 |
|
RJ01 | Rejection of invention patent application after publication |